Development of a 124I-labeled version of the anti-PSMA monoclonal antibody capromab for immunoPET staging of prostate cancer: Aspects of labeling chemistry and biodistribution.
about
Feasibility of Affibody Molecule-Based PNA-Mediated Radionuclide Pretargeting of Malignant TumorsThe therapeutic and diagnostic potential of the prostate specific membrane antigen/glutamate carboxypeptidase II (PSMA/GCPII) in cancer and neurological diseaseInfluence of Androgen Deprivation Therapy on the Uptake of PSMA-Targeted Agents: Emerging Opportunities and Challenges.Preclinical evaluation of a novel engineered recombinant human anti-CD44v6 antibody for potential use in radio-immunotherapy.Comparative Evaluation of Radioiodine and Technetium-Labeled DARPin 9_29 for Radionuclide Molecular Imaging of HER2 Expression in Malignant Tumors.
P2860
Development of a 124I-labeled version of the anti-PSMA monoclonal antibody capromab for immunoPET staging of prostate cancer: Aspects of labeling chemistry and biodistribution.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Development of a 124I-labeled ...... chemistry and biodistribution.
@en
Development of a 124I-labeled ...... chemistry and biodistribution.
@nl
type
label
Development of a 124I-labeled ...... chemistry and biodistribution.
@en
Development of a 124I-labeled ...... chemistry and biodistribution.
@nl
prefLabel
Development of a 124I-labeled ...... chemistry and biodistribution.
@en
Development of a 124I-labeled ...... chemistry and biodistribution.
@nl
P2093
P356
P1476
Development of a 124I-labeled ...... chemistry and biodistribution.
@en
P2093
Jennie Malmberg
Olof Eriksson
Sergio Estrada
P304
P356
10.3892/IJO.2014.2376
P577
2014-04-10T00:00:00Z